AC-262,536
Aliases: AC262536 · Accadrine
Last verified: 2026-09-23
The short version
A SARM with documented neuroprotection in Alzheimer's models (preclinical); anabolic effect ~2/3 of testosterone with minimal prostate effect in rats. Key fact: No controlled human trials exist. Everything known about AC-262,536 in humans comes from indirect sources and self-reports. Status: preclinical. Not approved; WADA-banned (S1).
Identity & type
- Molecular type
- SARM
- Origin
- A SARM with documented neuroprotection in Alzheimer's models (preclinical); anabolic effect ~2/3 of testosterone with minimal prostate effect in rats.
Mechanism of action
Selective AR agonism; cognitive effects via hippocampal AR.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for AC-262,536. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Community: 10–30 mg/day. Mild recomp and good tolerability are reported; some use it for the cognitive component. Few experiences.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
Mild recomp and good tolerability are reported; some use it for the cognitive component. Few experiences.
Protocol — official vs community
Official / label
No official protocol exists — this compound has no approved product.
Community (anecdotal)
10–30 mg oral daily.
- Cycle:
- 8 weeks.
- Break:
- 4 weeks; light PCT at the upper end of the range.
Used for mild recomp and tolerated well in self-reports; a subset of users picks it for the (entirely preclinical) cognitive rationale. Experiences are few enough that no real consensus exists.
Human evidence
No controlled human trials exist. Everything known about AC-262,536 in humans comes from indirect sources and self-reports.
Preclinical evidence
Preclinical (Acadia).
Known risks
- Unknown in humans.characterized
- WADA prohibition (S1 anabolic agents)characterized
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.